患者自控镇痛对微血管减压术患者术后恶心呕吐发生的影响:一项前瞻性随机对照试验
这项前瞻性、双盲、单中心随机对照试验于2021年12月至2023年2月纳入微血管减压术患者,术后随机分配至酮咯酸或芬太尼患者自控镇痛组,比较术后48小时内恶心呕吐发生率和严重程度及镇痛效果。结果显示酮咯酸组恶心呕吐发生率48.8% vs 芬太尼组79.5%(p=0.003),严重程度更低(p=0.004),补救止吐需求更少(p=0.049),停药更少(p=0.001),而术后疼痛无显著差异。
要点
- 酮咯酸组术后恶心呕吐发生率48.8%,低于芬太尼组的79.5%(p=0.003)。
- 酮咯酸组恶心呕吐严重程度低于芬太尼组(p=0.004),补救止吐需求更少(p=0.049)。
- 两组术后疼痛评分无显著差异,酮咯酸组停药例数更少(p=0.001)。
核心结论
- 在微血管减压术患者中,与芬太尼患者自控镇痛相比,酮咯酸患者自控镇痛降低了术后恶心呕吐的发生率和严重程度,镇痛效果与芬太尼相似。
- 本研究提供临床证据表明,酮咯酸患者自控镇痛可能成为芬太尼患者自控镇痛在术后护理中的有效替代方案。
研究设计与样本
- 前瞻性、双盲、单中心、随机对照试验,于2021年12月至2023年2月开展。
- 筛查185例患者,按预定排除标准排除91例,最终分析87例(酮咯酸组43例,芬太尼组44例)。
- 患者术后随机分配至酮咯酸或芬太尼患者自控镇痛组。
- 主要结局为术后48小时内恶心呕吐发生率,同时评估严重程度、补救止吐需求、术后疼痛评分、补救镇痛需求、患者自控镇痛使用情况及满意度评分。
主要发现
- 术后恶心呕吐发生率:酮咯酸组48.8% vs 芬太尼组79.5%(p=0.003),酮咯酸组更低。
- 术后恶心呕吐严重程度:酮咯酸组低于芬太尼组(p=0.004)。
- 补救止吐需求:酮咯酸组较芬太尼组显著减少(p=0.049)。
- 停药例数:酮咯酸组低于芬太尼组(p=0.001)。
- 术后疼痛:两组间无显著差异。
关键数值与推荐
- 恶心呕吐严重程度和术后疼痛评分采用11点数字评分量表(0=无,10=极度)。
- 恶心呕吐和疼痛满意度评分范围为0(非常不满意)至10(非常满意)。
临床怎么用
- 作者认为,酮咯酸患者自控镇痛可能成为芬太尼患者自控镇痛在微血管减压术后护理中的有效替代方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Postoperative nausea and vomiting (PONV) occurs frequently after microvascular decompression (MVD). Fentanyl, an opioid, is strongly related to the development of PONV, and ketorolac, a nonsteroidal anti-inflammatory drug, has been approved for postoperative pain management. However, how ketorolac-based patient-controlled analgesia (PCA) causes PONV or how its efficacy differs from that of fentanyl-based PCA after MVD is unclear. In this study, the authors compared ketorolac-based with fentanyl-based PCA in terms of the incidence and severity of PONV and analgesia after MVD. METHODS: This prospective, double-blind, single-center, randomized controlled trial conducted from December 2021 to February 2023 included patients with MVD who were randomly allocated to the ketorolac- or fentanyl-based PCA group postoperatively. The incidence (primary outcome) and severity of PONV and rescue antiemetic requirements were determined during the first 48 hours postoperatively. Additionally, postoperative pain scores, rescue analgesic requirement, PCA usage, and satisfaction scores were assessed during the study period. PONV severity and postoperative pain scores were assessed using an 11-point numeric rating scale (0 = none, 10 = extremely). Satisfaction scores for PONV and pain were determined (0 = very dissatisfied, 10 = very satisfied). Categorical variables were analyzed using the chi-square or Fisher's exact test. Continuous variables were analyzed using the Student t-test or Mann-Whitney U-test based on normal distribution. RESULTS: Of 185 screened patients, 91 were excluded based on predetermined exclusion criteria; 87 patients (43 in the ketorolac group and 44 in the fentanyl group) were analyzed and showed no significant differences in demographic data between groups. PONV incidence (48.8% vs 79.5%, p = 0.003) and severity (p = 0.004) were lower in the ketorolac-based PCA group than in the fentanyl-based PCA group. In the ketorolac group, there was a significant reduction in rescue antiemetic requirements compared with the fentanyl group (p = 0.049). The number of discontinuations was lower in the ketorolac-based PCA group than in the fentanyl-based PCA group (p = 0.001), whereas no significant differences in postoperative pain were found between the two groups. CONCLUSIONS: In patients with MVD, ketorolac-based PCA resulted in a decrease in PONV incidence and severity compared with fentanyl-based PCA, with analgesic effects similar to those of fentanyl-based PCA. This study provides clinical evidence that ketorolac-based PCA may be a valid alternative to fentanyl-based PCA in postoperative care.
引用
- Koo CH, Ji SY, Han JH, et al. Effect of patient-controlled analgesia on development of postoperative nausea and vomiting in patients undergoing microvascular decompression: a prospective randomized controlled trial. J Neurosurg. 2024. PMID: 38335521. doi:10.3171/2023.12.JNS231817
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。